Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118166) titled 'Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster' on Feb. 3.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Peking University Third Hospital
Condition:
Herpes Zoster
Intervention:
Control Group (Famciclovir Group):orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-08-25
Target Sample Size: Control Group (Famciclovir Group):70;Trial Group (Brivudine Group):70;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/sho...